Recently headlining at the European Society for Medical Oncology’s (ESMO) virtual World Congress on Gastrointestinal Cancer, 30 June – 03 July, 2021, results from a prospective study led by Elena Élez, Medical Oncologist and Clinical Investigator of VHIO’s Gastrointestinal & Endocrine Tumors Group, could advance insights into the molecular landscape of BRAF V600E metastatic colorectal cancer (mCRC) associated with sensitivity to BRAF inhibitors. Reported data also indicate the importance of integrating liquid biopsy analysis and comprehensive multi-sequencing in future prospective trials for this particular patient population.
Selected as a late-breaking abstract and published in ESMO’s flagship journal Annals of Oncology*, Elena Élez presented findings that point to the value of integrating the analysis of BRAFV600E mutant allele fraction (MAF) in cell-free DNA (dfDNA) and whole exome sequencing (WES) data to unveil predictive/prognostic biomarkers in BRAFV600E mCRC patients treated with BRAF/EGFR+/-MEK inhibitors.
Following her presentation, the ecancer online oncology platform caught up with Elena to discuss the study and how the results might impact the treatment of this tumor type. To access this virtual interview and hear what she had to say please click here, or visit https://ecancer.org/en/video.
This study was co-led by VHIO’s Director, Josep Tabernero, and VHIO Principal Investigators Ana Vivancos, Paolo Nuciforo, Héctor G. Palmer, Rodrigo Dienstmann, also including Javier Ros and Rodrigo A. Toledo and other VHIO researchers, alongside investigators headed by Fortunato Ciardiello at the Università degli studi della Campania Luigi Vanvitelli (Naples, Italy),
The ESMO 23rd World Congress on Gastrointestinal virtual Congress 2021 was chaired by our Director, Josep Tabernero, alongside Congress Vice Chair, Michel Ducreux, Institut Gustave Roussy (Villejuif, France), and Founding Chair, Eric Van Cutsem, University Hospital Gasthuisberg (Leuven, Belgium).
*LBA-3: Integrated analysis of Cell Free DNA (cfDNA) BRAF mutant allele fraction (MAF) and Whole Exome Sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF -antiEFGR +/-MEK Inhibitors. Ann Oncol 2021 July; 32(Suppl 3). DOI: https://doi.org/10. 1016/j.annonc.2021.06.010.